Corvus Pharmaceuticals Files 8-K on Shareholder Vote Matters

TL;DR

CRVS filed an 8-K about a shareholder vote. Details TBD.

AI Summary

Corvus Pharmaceuticals, Inc. filed an 8-K on June 14, 2024, reporting on matters submitted to a vote of security holders as of June 13, 2024. The filing does not contain specific details about the vote outcomes or the proposals presented.

Why It Matters

This filing indicates that Corvus Pharmaceuticals held a vote of its security holders, which could pertain to significant corporate decisions or governance changes.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose new financial information or material events that would immediately impact the company's risk profile.

Key Players & Entities

• Corvus Pharmaceuticals, Inc. (company) — Registrant
• June 13, 2024 (date) — Date of earliest event reported
• June 14, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market

Filing Documents

• f8k_061424.htm (8-K) — 26KB
• 0001171843-24-003444.txt ( ) — 196KB
• crvs-20240613.xsd (EX-101.SCH) — 3KB
• crvs-20240613_lab.xml (EX-101.LAB) — 33KB
• crvs-20240613_pre.xml (EX-101.PRE) — 22KB
• f8k_061424_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 13, 2024, Corvus Pharmaceuticals, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). Only stockholders of record at the close of business on April 18, 2024, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, there were 49,038,582 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 35,968,782 shares of the Company's common stock were voted in person or by proxy for the three proposals set forth below, each of which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 26, 2024. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows: Proposal No. 1 — Election of Director The Company's stockholders elected the Class II director nominee below to the Company's Board of Directors to hold office until the 2027 Annual Meeting of Stockholders or until his respective successor is elected and qualified or appointed, or the earlier of his death, resignation or removal. Class II Director Nominee Votes For Votes Withheld Broker Non - Votes Scott W. Morrison 19,667,286 5,398,946 10,902,550 Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm The Company's stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. Votes For Votes Against Abstain 35,776,658 65,997 126,127 Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers On a non-binding advisory basis, the Company's stockholders approved the compensation of the Company's named executive officers. Votes For Votes Agains

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORVUS PHARMACEUTICALS, INC. Date: June 14, 2024 By: /s/ Leiv Lea Leiv Lea Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR